الرئيسية › سرطان الرئة غير صغير الخلايا › كاليفورنيا › Sacramento
التجارب السريرية لـ سرطان الرئة غير صغير الخلايا في Sacramento، CA
29 دراسات لـ سرطان الرئة غير صغير الخلايا تبحث عن مشاركين في مواقع داخل وحول Sacramento (ضمن نطاق 30 ميلًا تقريبًا). افتح الدراسة لمعرفة من يمكنه المشاركة وكيفية التواصل مع فريق الدراسة.
النص الرسمي للدراسة (بالإنجليزية)
تبحث عن مشاركين لدراسة؟ أبرزها في أعلى الصفحة — $99 لمدة 30 يومًا →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
جارٍ التسجيلالمرحلة 3
- Kaiser Permanente Downtown Commons, Sacramento
- Sutter Medical Center Sacramento, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
- و 1 أخرى
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
جارٍ التسجيلالمرحلة 3
- UC Davis Comprehensive Cancer Center ( Site 3204), Sacramento
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
جارٍ التسجيلالمرحلة 3
- Kaiser Permanente Downtown Commons, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
- Kaiser Permanente-South Sacramento, Sacramento
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
جارٍ التسجيلالمرحلة 3
- Buhler Specialty Pavilion, Sacramento
- Sutter Medical Center, Sacramento Infusion Center, Sacramento
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
جارٍ التسجيلالمرحلة 2
- UC Davis Comprehensive Cancer Center, Sacramento
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
جارٍ التسجيلالمرحلة 3
- University of California Davis (UC Davis) Comprehensive Cancer Center, Sacramento
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- UC Davis Comprehensive Cancer Center, Sacramento
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
جارٍ التسجيلالمرحلة 2
- UC Davis Cancer Center (Data Collection Only), Sacramento
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
جارٍ التسجيلالمرحلة 2
- UC Davis Comprehensive Cancer Center, Sacramento
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
جارٍ التسجيلالمرحلة 1/2
- University of California Davis Comprehensive Cancer Center, Sacramento
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
جارٍ التسجيلالمرحلة 3
- University of California Davis Comprehensive Cancer Center, Sacramento
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
جارٍ التسجيلالمرحلة 2
- University of California Davis Comprehensive Cancer Center, Sacramento
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
جارٍ التسجيلالمرحلة 1/2
- University of California, Davis Comprehensive Cancer Center, Sacramento
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1
- University of California Davis Comprehensive Cancer Center, Sacramento
- University of California, Davis Medical Center, Sacramento
LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)
جارٍ التسجيل
- University of California, Davis, Sacramento
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
جارٍ التسجيلالمرحلة 1/2
- UC Davis, Davis Comprehensive Cancer Center, Sacramento
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
جارٍ التسجيلالمرحلة 3
- Sutter Institute for Medical Research, Sacramento
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
جارٍ التسجيلالمرحلة 2
- Kaiser Permanente Downtown Commons, Sacramento
- Sutter Medical Center Sacramento, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
جارٍ التسجيلالمرحلة 1
- University of California, Davis Comprehensive Cancer Center, Sacramento
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
جارٍ التسجيلالمرحلة 1
- University of California Davis, Sacramento
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
جارٍ التسجيلالمرحلة 2
- Sutter Medical Center Sacramento, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
جارٍ التسجيلالمرحلة 2/3
- Kaiser Permanente Downtown Commons, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
جارٍ التسجيلالمرحلة 2
- Sutter Medical Center Sacramento, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- University of California, Davis Comprehensive Cancer Center, Sacramento
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
جارٍ التسجيلدراسة رصدية
- Kaiser Permanente Downtown Commons, Sacramento
- Mercy Cancer Center - Sacramento, Sacramento
- Kaiser Permanente-South Sacramento, Sacramento
- و 1 أخرى
Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer
جارٍ التسجيلالمرحلة 1
- The University of California Davis Comprehensive Cancer Center, Sacramento
Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6
جارٍ التسجيلالمرحلة 1
- The University of California Davis Comprehensive Cancer Center, Sacramento
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
جارٍ التسجيلالمرحلة 1/2
- VA Northern California Health Care System, Mather, CA, Sacramento
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
جارٍ التسجيلالمرحلة 1
- University of California-Davis, Sacramento
تجارب سرطان الرئة غير صغير الخلايا في مدن أخرى
- Houston, TX145 دراسات
- New York City, NY121 دراسات
- Arlington, VA104 دراسات
- Nashville, TN97 دراسات
- Boston, MA90 دراسات
- Los Angeles, CA87 دراسات
- St. Louis, MO73 دراسات
- Chicago, IL61 دراسات
- Baltimore, MD60 دراسات
- San Antonio, TX59 دراسات
- Columbus, OH57 دراسات
- Washington, DC55 دراسات
دراسات أخرى في Sacramento
- سرطان الرئة22 دراسات
- سرطان الثدي20 دراسات
- سرطان البروستاتا19 دراسات
- السرطان النقيلي16 دراسات
- ابيضاض الدم النقوي الحاد12 دراسات
- قصور القلب12 دراسات
- سرطان البنكرياس12 دراسات
- السرطان (جميع الأنواع)11 دراسات
- سرطان القولون11 دراسات
- سرطان المثانة10 دراسات
- سرطان القولون والمستقيم10 دراسات
- السكري من النوع الثاني9 دراسات
من ClinicalTrials.gov، البيانات مستخرجة في 06/10/2026. كل دراسة تحدد معايير أهليتها الخاصة؛ فريق الدراسة هو من يحدد من يمكنه المشاركة.